SCHEMBL2704285

SCHEMBL2704285

COC(=O)c1ccc(I)c(C(=O)c2c(F)cccc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ IL2 P60568 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HCRTR1 O43613 1/20 0.42
▸ HCRTR2 O43614 1/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ PYGL P06737 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704221 0.86 KMT2A (0.55) ALDH1A1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL4694362 0.82 RORC (0.47) KDM4E
SCHEMBL27707943 0.78 KDM4E (0.58) ALDH1A1KMT2AHCRTR1HCRTR2MAPT
SCHEMBL17400893 0.77 CA1 (0.52) ALDH1A1KMT2AL3MBTL1HCRTR1HCRTR2
SCHEMBL4129856 0.76 KDM4E (0.50) ALDH1A1KMT2AHCRTR1HCRTR2RAB9A
SCHEMBL2705243 0.75 ALDH1A1 (0.55) ALDH1A1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL2509357 0.75 GAA (0.43) ALDH1A1KMT2ANPC1RAB9AGAA
SCHEMBL30824329 0.74 MAPT (0.53) ALDH1A1KMT2AHCRTR1HCRTR2MAPT
SCHEMBL15543900 0.74 CA1 (0.52) ALDH1A1KMT2AL3MBTL1HCRTR1HCRTR2
SCHEMBL1586780 0.74 CA12 (0.52) ALDH1A1KMT2AIL2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARM INC (US) 2024-03-14 — — US disclosed
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2022-02-10 — — US disclosed
US-11014928-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2021-05-25 — — US disclosed
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2020-08-06 — — US disclosed
US-10414770-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2019-09-17 — — US disclosed
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2018-05-17 — — US disclosed
US-9765078-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-09-19 — — US disclosed
EP-2719698-B1 Methods for preparing aurora kinase inhibitors MILLENNIUM PHARM INC (US) 2016-10-05 — — EP disclosed
EP-2746285-B1 Process for the preparation of aurora kinase inhibitors MILLENNIUM PHARM INC (US) 2016-09-14 — — EP disclosed
US-20160185782-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2016-06-30 — — US disclosed
EP-1905773-B1 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase MILLENNIUM PHARM INC (US) 2012-07-18 — — EP disclosed
EP-2261226-A1 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-15 — — EP disclosed
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-03 — — US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 — — US disclosed
EP-1771450-B9 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2008-12-24 — — EP disclosed
EP-1771450-B1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2007-12-19 — — EP disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 — — US disclosed
EP-1771450-A2 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-04-11 — — EP disclosed
WO-2005111039-A2 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-24 — — WO disclosed
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-10414770-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20180134716-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-11014928-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20160185782-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB ALDH1A1 3815/4885KMT2A 628/4885IL2 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback